Update – There is still time to make your submission to PBAC

January 18, 2024/Myasthenia Alliance Australia

[vc_row][vc_column][vc_custom_heading text=”Update – There is still time to make your submission to PBAC” font_container=”tag:h3|text_align:left|color:%23222222″ use_theme_fonts=”yes” el_class=”text-transform” css=”.vc_custom_1705534490612{margin-bottom: 30px !important;}”][vc_column_text]

Dear MG Community,
We hope the new year is off to a great start for you! The Myasthenia Alliance Australia (MAA) is sharing the attached information with you about the current opportunity to make a personal submission to the Pharmaceutical Benefits Advisory Committee (PBAC) about a new treatment called Ultomiris (Ravulizumab). 
 
Please read this in addition to the information we shared in December, which can also be accessed here: https://myastheniaalliance.org.au/information-about-making-a-pbac-submission-for-ravulizumab/
 
A reminder that the deadline for submissions is Wednesday, 31 January 2024. 
 
The Consumer Submission can be downloaded as a PDF from here:
The Consumer Submission can be downloaded as a Word document from here:
PBAC Consumer Submission for Ravulizumab – January 2024 (Part 2)

The Government’s Consumer Medicine Information (CMI) about Ultomiris (Ravulizumab) can be accessed via this link. 

Kind regards, 
The MAA Board

[/vc_column_text][/vc_column][/vc_row]

Posted in , ,